EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Edgewise Therapeutics, Inc. (EWTX) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B+ (3.7) | D- (0.9) | B- (2.9) | B- (3.1) | C+ (2.6) | C+ (2.7) |
| 2026-11-04 | C+ (2.5) | D- (0.9) | C+ (2.7) | B- (2.9) | C+ (2.7) | C (2.3) |
| 2026-10-28 | C+ (2.5) | F (0.2) | C+ (2.7) | B- (3.1) | C+ (2.7) | C (2.2) |
| 2026-10-21 | C+ (2.5) | F (0.2) | C+ (2.7) | B (3.2) | C+ (2.6) | C (2.2) |
| 2026-10-14 | C+ (2.5) | F (0.2) | C+ (2.7) | B- (3.1) | C+ (2.6) | C (2.2) |